Isofol Medical AB (publ) publishes year-end report, January – December 2021
GOTHENBURG, Sweden, February 24, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s year-end report […]
Listing Regulation
Isofol appoints nomination committee ahead of the Annual General Meeting 2022
GOTHENBURG, Sweden, November 19, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that
Isofol Medical AB (publ) publishes interim report for January – September 2021
GOTHENBURG, Sweden, November 11, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report
Isofol Medical AB (publ) publishes prospectus and new financial information in connection with listing on Nasdaq Stockholm
GOTHENBURG, Sweden, October 18, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol” or the
Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on June 23, 2021
Today on June 23, 2021 in Gothenburg – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), held
Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 400 million
GOTHENBURG, Sweden, May 25, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol or the
Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million
GOTHENBURG, Sweden, May 14, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the
New scientific findings strengthen rationale and motivation for Isofol Medical to conduct the pivotal ISO-CC-007 study
Isofol Medical AB (publ) announced today that academic researchers collaborating with Isofol have presented results last week at ESMO-GI which
Isofol Medical announces the outcome of the Offering – trading on Nasdaq First North Premier commences today
Isofol Medical AB (publ), a clinical stage pharmaceutical company, hereby announces that the offering of newly issued shares in the